Too Many Tests, Too Few Answers: The Hidden Harms of Diagnostic Overload

There is a widely held assumption in American healthcare that more information is always better—that ordering an additional blood panel, genetic screen, or imaging study is, at worst, a harmless precaution. It is an intuition that feels reasonable. It is also, according to a substantial and growing body of clinical research, frequently wrong.

The United States spends an estimated $210 billion annually on unnecessary medical tests and procedures, according to the National Academy of Medicine. A significant portion of that figure is attributable to laboratory testing—a category that has expanded dramatically in both volume and variety over the past two decades. What was once a carefully targeted clinical tool has, in many contexts, become a reflexive response to diagnostic uncertainty, patient demand, and institutional incentives that reward throughput over precision.

The Anatomy of Overtesting

Laboratory overutilization does not stem from a single cause. It emerges from the intersection of several distinct pressures operating simultaneously across the healthcare system.

Defensive medicine is among the most significant drivers. Physicians who fear malpractice litigation frequently order comprehensive panels not because clinical judgment demands them, but because a documented test result provides a degree of legal insulation. A 2010 survey published in the Archives of Internal Medicine found that 91 percent of physicians reported practicing defensive medicine, with unnecessary diagnostic testing cited as the most common manifestation.

Direct-to-consumer laboratory testing has added another dimension to the problem. Companies offering mail-order blood panels, microbiome analyses, food sensitivity screens, and genetic risk assessments have proliferated rapidly, capitalizing on consumers' desire for health transparency. While some of these services have genuine utility, many offer tests with limited clinical validity—producing data points that patients bring to their physicians without the interpretive context required to make them meaningful.

Algorithm-driven care protocols, increasingly embedded in electronic health record systems, can also inadvertently encourage overtesting. When a system flags a patient for a recommended annual panel without accounting for individual risk factors, clinical history, or prior results, it may generate testing activity that serves institutional metrics more than patient health.

The False Positive Problem

Perhaps the most clinically consequential consequence of excessive testing is the false positive—a result that suggests disease or abnormality in a patient who is, in fact, healthy. No diagnostic test is perfect; all carry a defined rate of false positive results, and that rate becomes clinically significant when tests are applied to low-risk populations.

Consider prostate-specific antigen (PSA) screening as an instructive example. The U.S. Preventive Services Task Force has issued nuanced guidance on PSA testing precisely because population-wide screening generates a substantial number of elevated results in men who do not have prostate cancer—leading to biopsies, anxiety, and in some cases treatment for cancers that would never have caused harm. The clinical harm from overdiagnosis and overtreatment in this context is well-documented and has informed ongoing revisions to screening recommendations.

The cascade effect is equally important to understand. A single ambiguous or falsely elevated result rarely ends the diagnostic journey—it typically initiates it. Follow-up imaging, repeat laboratory work, specialist consultations, and occasionally invasive procedures may all flow from a result that was never clinically meaningful in the first place. Each step in that cascade carries its own risks, costs, and opportunities for harm.

A landmark study in the BMJ estimated that for every 1,000 people undergoing low-dose CT screening for lung cancer, approximately 233 would receive a false positive result requiring follow-up—a figure that underscores how dramatically overtesting can amplify patient burden even in the context of a test with recognized screening value for high-risk populations.

Which Tests Actually Matter

Clinical value in laboratory testing is not static—it depends on age, individual risk profile, family history, and presenting symptoms. The following framework, informed by major U.S. clinical guidelines, offers a starting point for understanding where testing delivers meaningful benefit.

For adults aged 18–39 with no significant risk factors: Routine blood pressure measurement, cholesterol screening beginning at age 20 for those with risk factors, blood glucose testing if overweight or with family history of diabetes, and STI screening based on behavior and exposure represent the core of evidence-based preventive testing. Comprehensive metabolic panels ordered annually without specific indication offer limited incremental value in this population.

For adults aged 40–64: Colorectal cancer screening beginning at 45 (per American Cancer Society guidelines), diabetes screening every three years for those at elevated risk, and cardiovascular risk assessment using lipid panels and, where indicated, additional markers such as high-sensitivity C-reactive protein, become increasingly relevant. Thyroid function testing is warranted when symptoms are present, not as a routine annual screen in asymptomatic individuals.

For adults 65 and older: Bone density screening, abdominal aortic aneurysm ultrasound for male smokers, and continued colorectal and lung cancer screening (for eligible high-risk individuals) carry established evidence. Vitamin D testing, by contrast, is frequently ordered in this population without clear clinical indication—a pattern the Choosing Wisely campaign has specifically identified as an area of overuse.

The Choosing Wisely Movement and Its Limits

Launched in 2012 by the American Board of Internal Medicine Foundation, the Choosing Wisely initiative has done valuable work in cataloging specific tests and procedures that major medical specialty societies identify as commonly overused. More than 600 recommendations have been issued across dozens of specialties, covering everything from routine pre-operative testing to repeat imaging for uncomplicated conditions.

The initiative's impact on actual practice patterns, however, has been modest. Awareness among patients remains limited, and the structural incentives that drive overtesting—fee-for-service reimbursement models, liability concerns, patient expectations—have not been fundamentally altered by educational campaigns alone.

Having a More Productive Conversation With Your Provider

Patients are not passive recipients in this dynamic. Asking specific questions during clinical encounters can meaningfully influence testing decisions. Before agreeing to a laboratory order, it is reasonable to ask: What specific condition or risk are we screening for? How will a positive or negative result change my management? What is the likelihood of a false positive, and what would follow-up involve?

These are not adversarial questions—they are the questions a well-informed patient and a thoughtful clinician should be exploring together. Medicine at its best is not a matter of ordering everything available and sorting through the results. It is a disciplined process of asking the right questions, for the right patient, at the right time. Reclaiming that discipline—in an era of abundant but not always meaningful data—may be one of the most consequential things American healthcare can do.